Endovascular Ablation Of The Right Greater Splanchnic Nerve In Heart Failure With Preserved Ejection Fraction: Primary Results Of The REBALANCE-HF Randomized Trial

Sanjiv Shah,Sheldon Litwin,Teona Zirakashvili,Tamaz Shaburishvili,Parag Goyal,Scott Hummel,Rajeev Mohan,Matthew J. Price,Ravi Patel,Vivek Reddy,Daniel Burkhoff,Sami Somo,Manesh Patel,Barry Borlaug,Marat Fudim

DOI: https://doi.org/10.1016/j.cardfail.2023.10.464

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background In heart failure with preserved ejection fraction (HFpEF), increased sympathetic outflow to the splanchnic venous system is thought to cause excessive redistribution of blood volume into the central circulation, leading to elevated central venous and pulmonary capillary wedge pressure (PCWP), exercise limitations, hemodynamic deterioration, and worsening outcomes. Here we present the primary results of REBALANCE-HF, a feasibility trial evaluating a novel treatment paradigm: splanchnic ablation for volume management (SAVM) to improve hemodynamics, symptoms, exercise tolerance, and clinical outcomes in patients with HFpEF. Objective To assess the initial safety and efficacy of transvenous SAVM procedure by ablation of the right-sided greater splanchnic nerve (GSN) in HFpEF. Methods REBALANCE-HF is a phase 2, multicenter, randomized, sham-controlled trial. Patients with HF, LVEF ≥40%, and invasive peak exercise PCWP ≥25 mmHg were randomized 1:1 to SAVM (Axon Therapies, Santa Clara, CA) or a sham procedure. Baseline and follow-up assessments included resting and exercise PCWP, NYHA class, Kansas City Cardiomyopathy Questionnaire (KCCQ), 6-minute walk test (6MWT), and NTproBNP. The primary efficacy endpoint is a reduction in PCWP with legs up and at 20W exercise. The primary safety endpoint is serious device- or procedure-related adverse events at 1 month (adjudicated by an independent clinical events committee). Secondary endpoints included changes from baseline in NYHA, KCCQ, 6MWT, and NTproBNP at 1, 3, 6, and 12 months. Results A total of 90 HFpEF patients were randomized across 18 centers. The table lists the baseline characteristics. Participants were predominantly female (64%); with a median age of 71 years (IQR 63-78) and mean LVEF of 60% (IQR 57-62); and the majority were NYHA class III (90%). At baseline, the median peak PCWP was 36 mmHg (IQR 31-43). The primary safety and efficacy endpoints will be presented at HFSA with all available follow-up data (to 6 months). Conclusion The REBALANCE-HF trial—the first randomized, sham-controlled investigation of SAVM in HFpEF—will provide important data in the development of this novel transcatheter therapy to reduce excessive splanchnic vasoconstriction in HFpEF.

cardiac & cardiovascular systems